Principal Investigator: Professor Naveed Sattar
Department: Cardiovascular and Medical Sciences
Institution: University of GlasgowTags: 9310, biomarkers, cardiovascular disease, risk scores
Lead Collaborators: Dr David Preiss
Collaborating Institutions and Addresses: University of Oxford, Clincial Trial
Service, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3
Funding body: University of Glasgow
1a: In UK Biobank planned blood tests are important in helping detect early signs
of groups of related diseases in the heart, blood vessels, brain, as well as early
signs of diabetes. We will investigate to what extent these blood tests tell us
about how likely someone is to develop these conditions, how these conditions
develop, and whether we can intervene. For instance, adding information from
these tests might improve our ability to predict the risk of a person having a
heart attack. By harnessing the power of genes, we will test whether some of
these new markers cause disease.
1b: This project will aim to assess avenues to improve health care throughout
the population by investigating the improvement of CVD risk scores. More
sensitive CVD and related risk scores may lead to better targeting of treatment
and a reduction in the burden of CVD in the population.
1c: Biomarker measurement in UK biobank has been commenced, and the first
tranche of biomarkers to be measured are now known. We will assess whether
these markers are associated with, and predict, risk of cardiovascular and
metabolic-related conditions. Biomarkers of interest include:
Lipids and lipoproteins (different measures of blood cholesterol), markers of
inflammation, markers, of liver function, markers of renal function, sex
hormones, markers of glucose control, and markers of bone health. Each of
these has plausible biological mechanisms linking them to risk of cardiovascular
and metabolic diseases.
1d: The full cohort with available data will be explored to maximise
generalisability to the whole adult population.